Oncology

Latest News

Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC

Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC

By Alana Hippensteele, MA

September 8th 2025

Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.

Clinical Advances in EGFR-Mutated NSCLC: Insights From MARIPOSA and FLAURA2

Clinical Advances in EGFR-Mutated NSCLC: Insights From MARIPOSA and FLAURA2

By Alana Hippensteele, MA

September 7th 2025

Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC

Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC

By Alana Hippensteele, MA

September 7th 2025

Microscopic view of non small cell lung cancer cells. Image Credit: © Keopaserth - stock.adobe.com

From Amivantamab to Next-Generation Therapies: The Evolving Bispecific Antibody Landscape in NSCLC

By Alana Hippensteele, MA

September 6th 2025

Lung cancer. Image Credit: © Dr Microbe - stock.adobe.com

Comparing Global Standards in Lung Cancer: NCCN, ESMO, and CHEST Guidelines

By Alana Hippensteele, MA

September 6th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

September 10th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

September 10th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

September 12th 2017

MACRA Survey Finds Oncology Physicians Unprepared for Payment Changes

Surabhi Dangi-Garimella, PhD

A recent survey conducted by Integra Connect has found that a majority of specialty physicians have not yet invested in operational changes that may be essential for their success under value-based care reimbursement models.

September 12th 2017

ASCO Releases Guidelines on Patient—Clinician Communication

Christina Mattina

The American Society of Clinical Oncology (ASCO) has published a set of guidelines and best practices that can help clinicians improve how they communicate with patients receiving cancer therapy and their families.

September 11th 2017

The American Journal of Managed Care® Presents the Advanced Payment Models in Oncology Webcast Series

This webcast will discuss the Oncology Care Model from the perspective of a clinician and a payer.

September 11th 2017

ESMO 2017: Nivolumab-Ipilimumab Combination Reduced Risk of Death in RCC by 37%

Surabhi Dangi-Garimella, PhD

CheckMate-214 results presented at the European Society of Medical Oncology meeting show improved overall survival in patients with renal cell carcinoma treated with the nivolumab-ipilimumab combination, compared with sunitinib.

Dr Lee Newcomer on Policy Decisions as New Immunotherapy Agents Are Developed

September 10th 2017

Dr Lee Newcomer on Policy Decisions as New Immunotherapy Agents Are Developed

Lee N. Newcomer, MD, MHA, senior vice president of oncology and genetics at UnitedHealthcare, discusses off-label communications and how coverage determinations are changing along with the production of new immunotherapy agents.

September 10th 2017

Geographic Gaps in BRCA Testing Rates Have Narrowed

Christina Mattina

In recent years, testing for the BRCA1/2 gene mutations has increased among women in both metropolitan and nonmetropolitan areas, helping to drastically reduce the gap in testing rates between the groups.

Podcast: This Week in Managed Care - ACA Stabilization Proposals, and Other Health News

September 9th 2017

Podcast: This Week in Managed Care - ACA Stabilization Proposals, and Other Health News

Every week, The American Journal of Managed CareÂ® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

September 8th 2017

Cost Conversations in Oncology Care Led to Alternate Cost-Reducing Interventions

Surabhi Dangi-Garimella, PhD

Oncologist- as well as patient-initiated conversations on the cost of cancer care led to conversations on cost-reducing strategies 38% of the time, according to a new study published in the Journal of Oncology Practice.

This Week in Managed Care: September 8, 2017

September 8th 2017

This Week in Managed Care: September 8, 2017

This week, the top managed care stories included more insurers rolling back participation in Affordable Care Act exchanges, while governors testify ways to stabilize the market; the FDA put 3 combination trials of nivolumab on hold; and a study finds very few visits to the emergency department are truly avoidable.

September 8th 2017

Researchers Develop Pen Tool for Quickly Identifying Cancer Tissue During Surgery

Christina Mattina

“Is the pen mightier than the scalpel?” A new study aims to answer that question by presenting research on a handheld pen-sized device that can rapidly determine cancer tissue borders during surgery.

September 7th 2017

Following Pembrolizumab, Nivolumab Trials in Multiple Myeloma Paused

Surabhi Dangi-Garimella, PhD

Bristol-Myers Squibb announced that the FDA has placed a clinical hold on 3 combination trials evaluating its programmed death-1 inhibitor nivolumab (Opdivo) in patients with relapsed/refractory multiple myeloma.

September 6th 2017

Using Patient-Reported Distress to Guide the Timing of Palliative Care Conversations

Christina Mattina

After presenting research on the use of a patient-reported distress survey to guide the timing of palliative care discussions, lead author Stuart Goldberg, MD, chief scientific officer for Cota, Inc, discussed how it represents a shift in the paradigm of end-of-life conversations.

September 6th 2017

ctDNA Plus Protein Biomarker Test Allows Early Detection of Pancreatic Cancer

Surabhi Dangi-Garimella, PhD

A single blood draw that combines the detection of DNA and protein markers could be more sensitive to the earlier detection of pancreatic cancer, according to a new study published in Proceedings of the National Academy of Sciences.

September 5th 2017

Companies Continue to Face Challenges With Developing CAR-T Treatment

Surabhi Dangi-Garimella, PhD

Cellectis, a clinical-stage biotechnology company, was asked by the FDA to place a clinical hold on 2 phase 1 trials evaluating its allogeneic chimeric antigen receptor-T (CAR-T) cell treatments following the report of a fatality in the first patient treated in one of the studies.

September 5th 2017

Mammography Device Approved by FDA Gives Patients Control Over Pressure Levels

Christina Mattina

The FDA has approved the first 2D digital mammography system that lets patients adjust the level of compression applied to their breast during the imaging procedure.

September 4th 2017

Consistent Use of E-Cigarettes Can Help Smoking Cessation

According to a study published in The BMJ, while e-cigarettes can assist smokers to quit, the number of days of e-cigarette use will determine quit attempt and quit success.

September 4th 2017

Healthy, but Still Hurting: Challenges of Cancer Survivorship

Laura Joszt, MA

The assumption in the United States is that once someone with cancer is cured, done with treatment, and healthy, that they are now okay. However, the reality is that survivors contend with lingering challenges that aren’t visible and make it difficult for them to ask for help or admit they need it.

Dr Kashyap Patel Discusses Implementing the Oncology Care Model

September 4th 2017

Dr Kashyap Patel Discusses Implementing the Oncology Care Model

Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, explains how previous experience with alternative payment models helped a smooth transition into the Oncology Care Model (OCM).

Podcast: This Week in Managed Care - Hurricane Relief Efforts, and Other Health News

September 3rd 2017

Podcast: This Week in Managed Care - Hurricane Relief Efforts, and Other Health News

Every week, The American Journal of Managed CareÂ® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

September 1st 2017

A New Treatment Option for Newly Diagnosed AML: Gemtuzumab Ozogamicin

The treatment, which was approved nearly 2 decades ago but withdrawn due to safety and efficacy concerns, now has a new indication.

Dr Charlie Fazio on Balancing Different Delivery and Payment Models

September 1st 2017

Dr Charlie Fazio on Balancing Different Delivery and Payment Models

Charlie Fazio, MD, senior vice president and medical director of HealthPartners discusses how to balance different payment models in order to understand their impacts on cost and patient outcomes when they are implemented.

September 1st 2017

5 Significant Developments With CAR-T Therapy

Surabhi Dangi-Garimella, PhD

A look at some of the major developments in the chimeric antigen receptor T (CAR-T) cell space.

This Week in Managed Care: September 1, 2017

September 1st 2017

This Week in Managed Care: September 1, 2017

This week, the top managed care stories included responses to the disaster in Houston after Hurricane Harvey; the approval of the first gene therapy in the United States; and a new cardiovascular indication for a popular drug to treat type 2 diabetes.

September 1st 2017

FDA Emphasizes Risks of Pembrolizumab in Multiple Myeloma After Reviewing Halted Trials

Christina Mattina

Less than 2 months after it ordered a stop to 3 trials of pembrolizumab (Keytruda) in multiple myeloma due to safety concerns, the FDA has released a more detailed analysis of what went wrong in these trials.

August 31st 2017

Pembrolizumab Plus Epacadostat Yields Durable Response in Advanced Melanoma: ESMO

Surabhi Dangi-Garimella, PhD

Results of a combination trial evaluating epacadostat with pembrolizumab in advanced melanoma, to be presented at the upcoming European Society for Medical Oncology (ESMO) 2017 Congress, has found that the treatment is well tolerated and has promising clinical activity.

August 30th 2017

Race, Socioeconomic Status Linked to Rehospitalizations Among Patients With Advanced Cancer

Christina Mattina

A new study finds that individuals with advanced cancer have high rates of hospitalization in the year after diagnosis. Palliative care aimed at preventing hospital admissions may be a useful tool, especially for the populations most at risk of rehospitalization.

August 30th 2017

FDA Approves Tisagenlecleucel, the First CAR-T Cell Therapy in the United States

Laura Joszt, MA

The FDA has approved the first chimeric antigen receptor-T (CAR-T) treatment, tisagenlecleucel (Kymriah), for the treatment of B-cell precursor acute lymphoblastic leukemia in certain pediatric and young adult patients. The therapy represents a new frontier in cancer care.

August 29th 2017

FDA Approves Expanded Use of Fulvestrant as First-Line Hormonal Breast Cancer Therapy

Christina Mattina

AstraZeneca announced that the FDA has expanded the indications for fulvestrant (Faslodex). The drug is now approved as first-line monotherapy for women with certain types of breast cancer.

August 28th 2017

Ancestry Determines Effective and Harmful Dose in Breast Cancer

Surabhi Dangi-Garimella, PhD

A study published in JCO Precision Oncology has identified an association between genetic inheritance and patients’ response to efficacy and toxicity in the phase 3 ECOG-ACRIN-5103 trial.

August 25th 2017

Case Study Identifies New Trigger for CAR-T Cell Expansion in DLBCL in JCAR017 Trial

Surabhi Dangi-Garimella, PhD

Chimeric antigen receptor (CAR)-T cells can re-expand in a lymphoma patient months after the initial infusion and can also be active against the patient’s cancer, according to a new study.

...

69 70 71 72 73 74 75 76 77

...

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions